Year: 2023
Type: article
Abstract: The Great Debate session at the 2022 Melanoma Bridge congress (December 1-3) featured counterpoint views from leading experts on five contemporary topics of debate in the management of melanoma. The debates considered the choice of anti-lymphocyte-activation gene (LAG)-3 therapy or ipilimumab in combination with anti-programmed death (PD)-1 therapy, whether anti-PD-1 monotherapy is still acceptable as a comparator arm in clinical trials, whether adjuvant treatment of melanoma is still a useful treatment option, the role of adjuvant therapy in stage II melanoma, what role surgery will continue to have in the treatment of melanoma. As is customary in the Melanoma Bridge Great Debates, the speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect personal views. Audiences voted in favour of either side of the argument both before and after each debate.
Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", The Netherlands Cancer Institute, University Medical Center Utrecht, Princess Máxima Center, Technical University of Munich, Ludwig-Maximilians-Universität München, University of Tübingen, The University of Texas MD Anderson Cancer Center, Angeles Clinic and Research Institute, Christian-Albrechts-Universität zu Kiel, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Perugia, European Organisation for Research and Treatment of Cancer, Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,490
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron Pharmaceuticals, Jazz Pharmaceuticals, Les Laboratories Pierre Fabre, Tizona Therapeutics, Agios Pharmaceuticals, Mersana Therapeutics, BeiGene, Incyte, Galecto, Syndax Pharmaceuticals, SkylineDx, MacroGenics, Seagen, Eisai, Astellas Pharma, Sun Pharma, NeraCare, Genentech, EMD Serono
OpenAlex ID: W4366266963